Loading...

Valerio Therapeutics SA

ALVIO.PA•EURONEXT
Healthcare
Biotechnology
€0.05
€-0.00(-8.30%)

Valerio Therapeutics SA (ALVIO.PA) Stock Overview

Explore Valerio Therapeutics SA’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 59.6/100

Key Financials

Market Cap8.2M
P/E Ratio-0.44
EPS (TTM)$-0.14
ROE-2.09%
Fundamental Analysis

AI Price Forecasts

1 Week$0.07
1 Month$0.05
3 Months$0.06
1 Year Target$0.04

ALVIO.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Valerio Therapeutics SA (ALVIO.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.54, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.04.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.44 and a market capitalization of 8.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

53.54RSI (14)
0.00MACD
16.56ADX
Stats data is not available for ALVIO.PAStats details for ALVIO.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALVIO.PAAnalyst Recommendations details for ALVIO.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

CEO

Julien Miara

Employees

38

Headquarters

49, Bd du Général Martial Valin, Paris

Founded

2023

Frequently Asked Questions

;